Cargando…

Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial

BACKGROUND: Antagonizing the androgen-receptor (AR) pathway is an effective treatment strategy for patients with metastatic castration-resistant prostate cancer (CRPC). Here, we report the results of a first-in-human phase 1/2 study which assessed the safety, pharmacokinetics, and activity of SHR368...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Xiaojian, Ji, Dongmei, Gu, Weijie, Han, Weiqing, Luo, Hong, Du, Chuanjun, Zou, Qing, Sun, Zhongquan, He, Chaohong, Zhu, Shaoxing, Chong, Tie, Yao, Xin, Wan, Ben, Yang, Xinfeng, Bai, Aobing, Jin, Chunlei, Zou, Jianjun, Ye, Dingwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895828/ https://www.ncbi.nlm.nih.gov/pubmed/35241087 http://dx.doi.org/10.1186/s12916-022-02263-x

Ejemplares similares

A single‐centre, open‐label, single‐arm, fixed‐sequence pharmacokinetic study of SHR3680 on repaglinide and bupropion in prostate cancer patients
por: Dai, Tao, et al.
Publicado: (2022)

Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis
por: Sun, Rui, et al.
Publicado: (2023)

Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
por: Boudadi, Karim, et al.
Publicado: (2016)

Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy
por: Congregado Ruiz, Belén, et al.
Publicado: (2023)

Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer
por: Chen, Xiangyu, et al.
Publicado: (2023)

Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
por: Rice, Meghan A., et al.
Publicado: (2019)

Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer
por: Wu, Meng, et al.
Publicado: (2023)

High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice
por: Huhtaniemi, Riikka, et al.
Publicado: (2022)

Influence of statins in metastatic castration-resistant prostate cancer patients treated with new antiandrogen therapies: a systematic review and meta-analysis
por: Mariano, Renato, et al.
Publicado: (2022)

Targeting NF-kappa B Signaling by Artesunate Restores Sensitivity of Castrate-Resistant Prostate Cancer Cells to Antiandrogens()()
por: Nunes, Jessica J., et al.
Publicado: (2017)

Differentially expressed miR-3680-5p is associated with parathyroid hormone regulation in peritoneal dialysis patients
por: Jeong, Sohyun, et al.
Publicado: (2017)

A multicenter observational study of the real‐world use of docetaxel for metastatic castration‐resistant prostate cancer in China
por: He, Dalin, et al.
Publicado: (2019)

Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair
por: Elsesy, Mohamed E., et al.
Publicado: (2020)

The Shank3-InsG3680(+/+) mouse model of autism spectrum disorder displays auditory avoidance in a novel behavioral test
por: Gonçalves, Ana Margarida, et al.
Publicado: (2023)

Advantage of soybean isoflavone as antiandrogen on acne vulgaris
por: Riyanto, Puguh, et al.
Publicado: (2015)

Combining Antiandrogens with Immunotherapy for Bladder Cancer Treatment
por: Besançon, Marjorie, et al.
Publicado: (2022)

First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects
por: Chen, Rui, et al.
Publicado: (2022)

Designer antiandrogens join the race against drug resistance
por: Josan, Jatinder S, et al.
Publicado: (2013)

Reversing resistance to antiandrogens with a histone deacetylase inhibitor
por: Ferrari, Anna C.
Publicado: (2018)

Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?
por: Maitland, Norman J.
Publicado: (2021)

Rational Second-Generation Antiandrogen Use in Prostate Cancer
por: Orme, Jacob J, et al.
Publicado: (2022)

Use of Antiandrogens as Therapeutic Agents in COVID-19 Patients
por: Giotis, Efstathios S., et al.
Publicado: (2022)

Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study
por: Qu, Yuan-Yuan, et al.
Publicado: (2022)

Three May Be Better Than Two: A Proposal for Metformin Addition to PI3K/Akt Inhibitor-antiandrogen Combination in Castration-resistant Prostate Cancer
por: Delma, Mohamed Islam
Publicado: (2018)

Antiandrogen-Equipped Histone Deacetylase Inhibitors Selectively Inhibit Androgen Receptor (AR) and AR-Splice Variant (AR-SV) in Castration-Resistant Prostate Cancer (CRPC)
por: Chandrasekaran, Balaji, et al.
Publicado: (2023)

Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study
por: Zhao, Jin-Ge, et al.
Publicado: (2018)

Spatial Memory in Spontaneously Hypertensive Rats (SHR)
por: Sontag, Thomas-A., et al.
Publicado: (2013)

Antiandrogenic activity and metabolism of the organophosphorus pesticide fenthion and related compounds.
por: Kitamura, Shigeyuki, et al.
Publicado: (2003)

Overcoming mutation-based resistance to antiandrogens with rational drug design
por: Balbas, Minna D, et al.
Publicado: (2013)

Persistent genital arousal disorder: Successful treatment with leuprolide (antiandrogen)
por: Deka, Kamala, et al.
Publicado: (2015)

Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms
por: Verma, Shiv, et al.
Publicado: (2020)

Physicochemical Profile of Antiandrogen Drug Bicalutamide: Solubility, Distribution, Permeability
por: Volkova, Tatyana V., et al.
Publicado: (2022)

Antiandrogenic treatment of obsessive compulsive neurosis: A case review
por: Huerga García, L., et al.
Publicado: (2023)

Cardioprotective Regimen of Adaptation to Chronic Hypoxia Diversely Alters Myocardial Gene Expression in SHR and SHR-mt(BN) Conplastic Rat Strains
por: Nedvedova, Iveta, et al.
Publicado: (2019)

Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study
por: Tang, Honghu, et al.
Publicado: (2022)

Vasorelaxant and Hypotensive Effects of Cheonwangbosimdan in SD and SHR Rats
por: Kim, Bumjung, et al.
Publicado: (2018)

Upregulation of lncRNA LANCL1-AS1 inhibits the progression of non-small-cell lung cancer via the miR-3680-3p/GMFG axis
por: Pan, Hui, et al.
Publicado: (2023)

Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single‐center, open‐label phase I trial
por: Deng, Kunhong, et al.
Publicado: (2022)

Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland
por: Pan, Jian, et al.
Publicado: (2022)

Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants – In vivo evidence
por: Özten-Kandaş, Nur, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_p8r32r9b5d6be87in0dnrf52c7